Hadasit Bio-Holdings Cultivates Good Science




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Hadasit Bio-Holdings Cultivates Good Science
Released on: February 24, 2009. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    With nine early stage companies in its portfolio at the start of 2009, Hadasit Bio-Holdings (HBL) may seem to some to be facing a tough year ahead.
  • Summary
  • Participants
  • Company
With nine early stage companies in its portfolio at the start of 2009, Hadasit Bio-Holdings (HBL) may seem to some to be facing a tough year ahead. Ophir Shahaf, CEO, whilst recognising the challenge, has a plan in place and over the next 18 months hopes to take five or six through into clinical trials. Here he discusses the expected outcome of these young companies and how HBL intends to make sure they reach their full potential.
Ophir Shahaf
Managing Director
Hadasit Bio-Holdings Ltd

Ophir Shahaf was appointed to the position of Managing Director of Hadasit Bio-Holdings Ltd. - the publicly traded subsidiary of Hadasit, upon its IPO – in January 2006. He was promoted to the position of CEO in March, 2007. Mr. Shahaf is responsible for all of the ongoing activities of the public entity, including financial, legal, IR/PR, investment and fundraising issues.

Prior to this position, he served as VP business development at Protalix Biotherapeutics Ltd., a biopharmaceutical company focusing on the expression of human recombinant proteins in plant cell cultures. Adv. Shahaf was a part of the founding and management team of Clal Biotechnology Industries Ltd. – Israel's largest corporate investor in the life sciences, where he served as VP and general counsel, and participated in the management and investment of over $ 100 M.

Mr. Shahaf received his law degree from Tel Aviv University, and his MBA from the Stern School of Business at New York University, with a major in finance and international business. He teaches several courses in biotechnology entrepreneurship and management and is a fellow of the Merage Foundation at Irvine, CA.
Hadasit Bio-Holdings